| Q36887707 | A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer |
| Q53842727 | A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. |
| Q54409274 | Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate. |
| Q26830671 | Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis |
| Q37029385 | Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools |
| Q33414685 | Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus |
| Q37268981 | Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus |
| Q55237889 | Advances in prostate cancer research models: From transgenic mice to tumor xenografting models. |
| Q36610246 | An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy |
| Q38833458 | Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. |
| Q51033341 | Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. |
| Q39634850 | Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer |
| Q42119481 | Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion |
| Q55399069 | Biomarkers in active surveillance. |
| Q90082711 | Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial |
| Q36965321 | Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression |
| Q35101357 | Can we accurately report PTEN status in advanced colorectal cancer? |
| Q38151298 | Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? |
| Q42356687 | Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG. |
| Q63866039 | Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer |
| Q36193912 | Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. |
| Q39023426 | Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease |
| Q49818398 | Clinical implications of PTEN loss in prostate cancer |
| Q34498069 | Clonal progression of prostate cancers from Gleason grade 3 to grade 4. |
| Q30557008 | Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer |
| Q37221588 | Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer |
| Q37536970 | Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. |
| Q89767735 | Copy number alterations are associated with metastatic-lethal progression in prostate cancer |
| Q89586700 | Could the kinetin riboside be used to inhibit human prostate cell epithelial-mesenchymal transition? |
| Q38042634 | Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers |
| Q36724548 | Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia |
| Q38774228 | DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer |
| Q35873154 | Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer |
| Q38160495 | Disruption of prostate epithelial differentiation pathways and prostate cancer development |
| Q40544225 | Distinct expression profile of key molecules in crawling-type early gastric carcinoma |
| Q37091474 | Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder |
| Q43269413 | ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression. |
| Q38165243 | ERG protein expression as a biomarker of prostate cancer. |
| Q57281248 | Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis |
| Q42673080 | Expression and prognostic significance of ELL-associated factor 2 in human prostate cancer |
| Q30573750 | Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. |
| Q55689982 | Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss? |
| Q39170943 | Genomic tests to guide prostate cancer management following diagnosis |
| Q85804519 | High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral |
| Q98945179 | High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts |
| Q92289172 | HoxB13 expression in ductal type adenocarcinoma of prostate: clinicopathologic characteristics and its utility as potential diagnostic marker |
| Q36753720 | Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence |
| Q41657305 | Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma |
| Q91669799 | If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease |
| Q33642302 | Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas |
| Q39307061 | Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases |
| Q37080378 | In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity |
| Q40919195 | In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading |
| Q96126040 | Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming |
| Q26752510 | Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics |
| Q37082536 | Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors |
| Q30381117 | Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. |
| Q35854235 | Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer |
| Q38134734 | Intraductal carcinoma of prostate: a comprehensive and concise review |
| Q47758797 | Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery |
| Q35586422 | Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis |
| Q51549809 | Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. |
| Q35234584 | Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer |
| Q47976701 | MSH2 Loss in Primary Prostate Cancer |
| Q47829840 | MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. |
| Q91661243 | Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease |
| Q36199762 | Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer |
| Q27005677 | Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN |
| Q38280833 | Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model |
| Q50133991 | Molecular Biomarkers in the Clinical Management of Prostate Cancer. |
| Q27024775 | Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer |
| Q36469889 | Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization |
| Q42184292 | Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues |
| Q34365632 | Molecular pathways and targets in prostate cancer |
| Q40740686 | Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy |
| Q35176084 | Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients |
| Q47664729 | Mucinous and secondary tumors of the prostate |
| Q27001047 | Notch signaling in prostate cancer: a moving target |
| Q53550490 | Novel Assay to Detect RNA Polymerase I Activity In Vivo. |
| Q36901964 | Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma |
| Q41004851 | Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer |
| Q38206682 | PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance |
| Q38599066 | PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer |
| Q39401816 | PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer |
| Q36235829 | PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors |
| Q38541293 | PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis. |
| Q45904675 | PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer. |
| Q41907553 | PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas |
| Q41912121 | PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. |
| Q42371556 | PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort |
| Q45251986 | PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer |
| Q36287422 | PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients |
| Q43089446 | PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy |
| Q35540013 | PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. |
| Q57049913 | PTEN status assessment in the Johns Hopkins active surveillance cohort |
| Q36269232 | Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance |
| Q91881793 | Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort |
| Q34371057 | Prevention and early detection of prostate cancer |
| Q90170218 | Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues |
| Q38628081 | Prognostic and predictive biomarkers in prostate cancer |
| Q38184382 | Prognostic prostate tissue biomarkers of potential clinical use. |
| Q42748239 | Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer |
| Q36959119 | Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. |
| Q35132292 | Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas |
| Q38321512 | Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. |
| Q37476043 | Prostate cancer: the need for biomarkers and new therapeutic targets |
| Q50141035 | Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides. |
| Q39044979 | Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma |
| Q38779933 | Recent advances in prostate cancer pathology: Gleason grading and beyond |
| Q33852664 | Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment |
| Q49721870 | Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder. |
| Q90253669 | Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA |
| Q90029848 | Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN) |
| Q61445176 | SP1 and RARα regulate AGAP2 expression in cancer |
| Q53644292 | SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. |
| Q38850627 | STAT3 regulated ARF expression suppresses prostate cancer metastasis |
| Q36931932 | Should Gleason 6 be labeled as cancer? |
| Q38967389 | Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers |
| Q42436743 | Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers |
| Q51586225 | TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer. |
| Q91127371 | The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status |
| Q90029873 | The Challenges of Optimizing Biomarkers To Guide Clinical Decision Making |
| Q57073785 | The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature |
| Q91114591 | The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy |
| Q38983790 | The molecular underpinnings of prostate cancer: impacts on management and pathology practice |
| Q41762568 | Tracking the clonal origin of lethal prostate cancer |
| Q30572057 | Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases |
| Q43104641 | Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy |
| Q38540198 | Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer |
| Q53108923 | [Focal therapy of prostate cancer in Germany]. |
| Q57848625 | deletion in luminal cells of mature prostate induces replication stress and senescence in vivo |
| Q36742601 | miR-21 Is Linked to Glioma Angiogenesis: A Co-Localization Study |
| Q47231171 | p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer |